It’s not clear whether the orca is a true albino or its white coloring was caused by another medical condition.
Orca Bio has shared promising results from a late-stage study of its investigational allogeneic T-cell immunotherapy in ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
It’s not clear whether the orca is a true albino or its white coloring was caused by another medical condition.
BANGKOK (AP) — China’s leading supplier of LiDAR technology has denied a report saying it has links to the Chinese military, ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...
Hesai Group (NASDAQ: HSAI) shares traded lower on Tuesday after short seller Blue Orca Capital released a report accusing the ...
Ripple CEO Brad Garlinghouse sees closely related XRP as part of the White House’s proposed digital asset stockpile and ...
Hesai Group shares are down in premarket trading on Wednesday following allegations by short seller Blue Orca Capital, who accused the company of misleading investors and having ties to the Chinese ...
GlobalData on MSN1d
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patientsGraft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as foreign and rejects them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback